1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)-
1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)- Basic information
- Product Name:
- 1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)-
- Synonyms:
-
- 1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)-
- MS140
- XY028-140
- CDK6,CDK4,PROTACs,anticancer,XY028140,Cyclin dependent kinase,XY-028-140,XY028 140,CDK,inhibit,Inhibitor
- XY028-140 (MS140)
- 4-((2-(4-(6-((6-Acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)piperazin-1-yl)-2-oxoethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione
- CAS:
- 2229974-83-6
- MF:
- C39H40N10O7
- MW:
- 760.8
- Mol File:
- 2229974-83-6.mol
More
Less
1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)- Chemical Properties
- Density
- 1.482±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO : 5.56 mg/mL (7.31 mM; ultrasonic and warming and heat to 60°C)
- form
- Solid
- pka
- 10.74±0.40(Predicted)
- color
- White to yellow
More
Less
1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)- Usage And Synthesis
Biological Activity
XY028-140 is a selective CDK4/CDK6 degrader. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity in cancer cells[1]. A375 melanoma and T47D breast cancer cells are treated with 0.3 or 1 μμ XY028-140 for 24 hours. XY028-140 inhibits both CDK4/6 expression and CDK4/6 activity[1]. T47D breast cancer cells are treated with 0.03, 0.1, 0.3, 1, or 3 μμ XY028-140 for 11 days. XY028-140 inhibits cancer cell proliferation in breast cancer cells[1].
References
[1]. Jian Jin, et al. Compositions and methods for treating cdk4/6-mediated cancer. WO2018106870A1.
1H-Isoindole-1,3(2H)-dione, 4-[[2-[4-[6-[(6-acetyl-8-cyclopentyl-7,8-dihydro-5-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl)amino]-3-pyridinyl]-1-piperazinyl]-2-oxoethyl]amino]-2-(2,6-dioxo-3-piperidinyl)-Supplier
ShangHai Caerulum Pharma Discovery Co., Ltd.
- Tel
- 18149758185 18149758185
- sales-cpd@caerulumpharma.com
Shanghai EFE Biological Technology Co., Ltd.
- Tel
- 021-65675885 18964387627
- info@efebio.com
ShangHai Biochempartner Co.,Ltd
- Tel
- 17754423994 17754423994
- 2853530910@QQ.com
Jilin Province Woda Biotechnology Co., Ltd.
- Tel
- 13504435624
- 1927928688@qq.com
TargetMol Chemicals Inc.
- Tel
- +1-781-999-5354 +1-00000000000
- marketing@targetmol.com